|
1
|
Akaza H: Asian trends in primary androgen
depletion therapy on prostate cancer. Cancer Biol Med. 10:187–191.
2013.PubMed/NCBI
|
|
2
|
Baade PD, Youlden DR, Cramb SM, Dunn J and
Gardiner RA: Epidemiology of prostate cancer in the Asia-Pacific
region. Prostate Int. 1:47–58. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rosenthal SA and Sandler HM: Treatment
strategies for high-risk locally advanced prostate cancer. Nat Rev
Urol. 7:31–38. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen Y, Clegg NJ and Scher HI:
Anti-androgens and androgen-depleting therapies in prostate cancer:
New agents for an established target. Lancet Oncol. 10:981–991.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Damber JE and Aus G: Prostate cancer.
Lancet. 371:1710–1721. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Taplin ME: Drug insight: Role of the
androgen receptor in the development and progression of prostate
cancer. Nat Clin Pract Oncol. 4:236–244. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sullivan GF, Amenta PS, Villanueva JD,
Alvarez CJ, Yang JM and Hait WN: The expression of drug resistance
gene products during the progression of human prostate cancer. Clin
Cancer Res. 4:1393–1403. 1998.PubMed/NCBI
|
|
8
|
Chen CD, Welsbie DS, Tran C, Baek SH, Chen
R, Vessella R, Rosenfeld MG and Sawyers CL: Molecular determinants
of resistance to antiandrogen therapy. Nat Med. 10:33–39. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Agus DB, Cordon-Cardo C, Fox W, Drobnjak
M, Koff A, Golde DW and Scher HI: Prostate cancer cell cycle
regulators: Response to androgen withdrawal and development of
androgen independence. J Natl Cancer Inst. 91:1869–1876. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wissenbach U, Niemeyer BA and Flockerzi V:
TRP channels as potential drug targets. Biol Cell. 96:47–54. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Prevarskaya N, Zhang L and Barritt G: TRP
channels in cancer. Biochim Biophys Acta. 1772:937–946. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tsavaler L, Shapero MH, Morkowski S and
Laus R: Trp-p8, a novel prostate-specific gene, is up-regulated in
prostate cancer and other malignancies and shares high homology
with transient receptor potential calcium channel proteins. Cancer
Res. 61:3760–3769. 2001.PubMed/NCBI
|
|
13
|
Henshall SM, Afar DE, Hiller J, Horvath
LG, Quinn DI, Rasiah KK, Gish K, Willhite D, Kench JG,
Gardiner-Garden M, et al: Survival analysis of genome-wide gene
expression profiles of prostate cancers identifies new prognostic
targets of disease relapse. Cancer Res. 63:4196–4203.
2003.PubMed/NCBI
|
|
14
|
Okamoto Y, Ohkubo T, Ikebe T and Yamazaki
J: Blockade of TRPM8 activity reduces the invasion potential of
oral squamous carcinoma cell lines. Int J Oncol. 40:1431–1440.
2012.PubMed/NCBI
|
|
15
|
Yee NS, Brown RD, Lee MS, Zhou W, Jensen
C, Gerke H and Yee RK: TRPM8 ion channel is aberrantly expressed
and required for preventing replicative senescence in pancreatic
adenocarcinoma: Potential role of TRPM8 as a biomarker and target.
Cancer Biol Ther. 13:592–599. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang L and Barritt GJ: Evidence that
TRPM8 is an androgen-dependent Ca2+ channel required for
the survival of prostate cancer cells. Cancer Res. 64:8365–8373.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Valero ML, de Queiroz Mello F, Stühmer W,
Viana F and Pardo LA: TRPM8 ion channels differentially modulate
proliferation and cell cycle distribution of normal and cancer
prostate cells. PloS One. 7:e518252012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Madrid R, Donovan-Rodríguez T, Meseguer V,
Acosta MC, Belmonte C and Viana F: Contribution of TRPM8 channels
to cold transduction in primary sensory neurons and peripheral
nerve terminals. J Neurosci. 26:12512–12525. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mergler S, Mertens C, Valtink M, Reinach
PS, Székely VC, Slavi N, Garreis F, Abdelmessih S, Türker E, Fels G
and Pleyer U: Functional significance of thermosensitive transient
receptor potential melastatin channel 8 (TRPM8) expression in
immortalized human corneal endothelial cells. Exp Eye Res.
116:337–439. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Alao JP: The regulation of cyclin D1
degradation: Roles in cancer development and the potential for
therapeutic invention. Mol Cancer. 6:242007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Trudeau ME: Docetaxel: a review of its
pharmacology and clinical activity. Can J Oncol. 6:443–457.
1996.PubMed/NCBI
|
|
22
|
Kulkarni P: TRPM8 and prostate cancer: To
overexpress or repress, that is the question-comment on “Effects of
TRPM8 on proliferation and motility of prostate cancer PC-3 cells”
by Yang ZH et al in Asian Journal of Andrology. Asian J
Androl. 11:150–151. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Flourakis M and Prevarskaya N: Insights
into Ca2+ homeostasis of advanced prostate cancer cells.
Biochim Biophys Acta. 1793:1105–1109. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yang ZH, Wang XH, Wang HP and Hu LQ:
Effects of TRPM8 on the proliferation and motility of prostate
cancer PC-3 cells. Asian J Androl. 11:157–165. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang Y, Wang X, Yang Z, Zhu G, Chen D and
Meng Z: Menthol inhibits the proliferation and motility of prostate
cancer DU145 cells. Pathol Oncol Res. 18:903–910. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mälkiä A, Madrid R, Meseguer V, de la Peña
E, Valero M, Belmonte C and Viana F: Bidirectional shifts of TRPM8
channel gating by temperature and chemical agents modulate the cold
sensitivity of mammalian thermoreceptors. J Physiol. 581:155–174.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Valero M, Morenilla-Palao C, Belmonte C
and Viana F: Pharmacological and functional properties of TRPM8
channels in prostate tumor cells. Pflugers Arch. 461:99–114. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Parsons JT, Slack-Davis J, Tilghman R and
Roberts WG: Focal adhesion kinase: Targeting adhesion signaling
pathways for therapeutic intervention. Clin Cancer Res. 14:627–632.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Slack JK, Adams RB, Rovin JD, Bissonette
EA, Stoker CE and Parsons JT: Alterations in the focal adhesion
kinase/Src signal transduction pathway corassociate with increased
migratory capacity of prostate carcinoma cells. Oncogene.
20:1152–1163. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Page-McCaw A, Ewald AJ and Werb Z: Matrix
metalloproteinases and the regulation of tissue remodelling. Nat
Rev Mol Cell Biol. 8:221–233. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
MacCorkle RA and Tan TH: Mitogen-activated
protein kinases in cell-cycle control. Cell Biochem Biophys.
43:451–461. 2005. View Article : Google Scholar : PubMed/NCBI
|
